Key result
Czech patients with chronic systolic heart failure of ischemic etiology had a significantly lower overall mortality compared to the overall trial population (26.2% vs. 29.7%, p < 0.01) despite having more cardiovascular risk factors.
Observational (n=5,011)
Yes
Absolute Event Rate: 26.2% vs 29.7%
Absolute Risk Reduction: 3.5%
p-value: p=<0.01
Czech patients with ischemic systolic heart failure had a higher burden of comorbidities but lower overall mortality compared to the broader European cohort in the CORONA trial, though guideline-directed medical therapy was frequently underdosed.
Regional mortality differences in ischemic HF warrant caution against broad extrapolation; leaves open questions on care variations or selection in trial cohorts.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hradec et al. (2009) conducted an observational in Chronic systolic heart failure of ischemic etiology (n=5,011). Czech Republic healthcare setting vs. Overall CORONA trial population was evaluated on Overall mortality (p=<0.01). Czech patients with chronic systolic heart failure of ischemic etiology had a significantly lower overall mortality compared to the overall trial population (26.2% vs. 29.7%, p < 0.01) despite having more cardiovascular risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: